Table 2 Anti-tumor activity in TCAC and TCC.

From: Anlotinib plus camrelizumab and chemotherapy as first-line treatment in patients with advanced esophageal squamous cell carcinoma

Best responses

TCAC (n = 30)

TCC (n = 30)

P

CR, n(%)

3(10.0)

1 (3.3)

/

PR, n(%)

24 (80.0)

12(40.0)

/

SD, n(%)

3 (10.0)

16 (53.3)

/

PD, n(%)

0 (0.0)

1 (3.3)

/

ORR, n(%, 95%CI)

27(90, 73.5–97.9)

13(43.3, 25.5–62.6)

< 0.001

DCR, n(%, 95%CI)

30(100.0, 88.4–100.0)

29(96.7, 82.8–99.9)

/

DpR ≥ 50%, n(%,95%CI)

15(50.0,31.3–68.7)

6(20.0,7.7–38.6)

0.029

DpR(Mean ± SD—%)

53.80 ± 24.95

29.64 ± 29.81

0.001

  1. CI Confidence Interval, ORR Objective OesponseOate, DCR Disease Control Rate, DpR Depth of Response, PFS Progression-free Survival.
  2. 95% CIs were computed via the Clopper-Pearson exact method.
Back to article page